Health Plans' Limits on Hep C Drug Coverage Leads to Tension

By Alao Mayo, Hall Render Killian Heath & Lyman PC

High price tags for new therapies like Gilead’s Harvoni and Sovaldi and AbbVie’s Viekira Pak are creating tension between payers, providers and now patients. A new lawsuit questions the legitimacy of insurer-imposed restrictions placed on access to these promising new hepatitis C drugs. Read more here. 

This post was written by Alao Mayo of Hall Render Killian Heath & Lyman PC. If you would like to submit content or write an article for the Health Care and Life Sciences Section page, please email Rachel Beachy at rbeachy@indybar.org.